Previous Page
18
nanotimes
Companies Facts
B
IND Biosciences announced the presentation of late-breaker clinical data for BIND-014, the
lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting. BIND pre- sented data from the ongoing Phase 1 clinical study of BIND-014, its targeted docetaxel Accurin™, in pa- tients with solid tumors that strongly translated from preclinical data, demonstrated safety and tolerability, and showed evidence of anti-tumor activity with
six of 17 patients with advanced or metastatic solid tumor cancers. The preliminary Phase 1 data de- monstrated partial response or stable disease in this heavily pretreated patient population with durable responses of up to six months in some cases. In addi- tion, BIND-014 demonstrated evidence of anti-tumor activity in tumors for which conventional docetaxel is known to have minimal activity.
12-03 :: March/April 2012
Advertisement